Literature DB >> 16027517

Liposomal encapsulated anti-cancer drugs.

Ralf-Dieter Hofheinz1, Senta Ulrike Gnad-Vogt, Ulrich Beyer, Andreas Hochhaus.   

Abstract

Among several drug delivery systems, liposomal encapsulated anti-cancer agents represent an advanced and versatile technology. Several formulations of liposomal anthracyclines are approved, e.g. for the treatment of metastatic breast cancer (pegylated and non-pegylated liposomal doxorubicin) or AIDS-related Kaposi's sarcoma (pegylated liposomal doxorubicin and liposomal daunorubicin). Meanwhile, virtually all anti-cancer drugs have been encapsulated in liposomes using different technologies. This review will summarize preclinical and clinical data of approved and exemplary emerging liposomal anti-cancer agents.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16027517     DOI： 10.1097/01.cad.0000167902.53039.5a

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN： 0959-4973            Impact factor:   2.248


  60 in total

Review 1.  Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research.

Authors:  Susana Patricia Egusquiaguirre; Manuela Igartua; Rosa María Hernández; José Luis Pedraz
Journal:  Clin Transl Oncol       Date:  2012-02       Impact factor: 3.405

Review 2.  Polymeric nanogel formulations of nucleoside analogs.

Authors:  Serguei V Vinogradov
Journal:  Expert Opin Drug Deliv       Date:  2007-01       Impact factor: 6.648

Review 3.  Nanoparticles: pharmacological and toxicological significance.

Authors:  C Medina; M J Santos-Martinez; A Radomski; O I Corrigan; M W Radomski
Journal:  Br J Pharmacol       Date:  2007-01-22       Impact factor: 8.739

Review 4.  Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer.

Authors:  Daniel C Julien; Steven Behnke; Guankui Wang; Gordon K Murdoch; Rodney A Hill
Journal:  MAbs       Date:  2011-09-01       Impact factor: 5.857

Review 5.  Enabling individualized therapy through nanotechnology.

Authors:  Jason H Sakamoto; Anne L van de Ven; Biana Godin; Elvin Blanco; Rita E Serda; Alessandro Grattoni; Arturas Ziemys; Ali Bouamrani; Tony Hu; Shivakumar I Ranganathan; Enrica De Rosa; Jonathan O Martinez; Christine A Smid; Rachel M Buchanan; Sei-Young Lee; Srimeenakshi Srinivasan; Matthew Landry; Anne Meyn; Ennio Tasciotti; Xuewu Liu; Paolo Decuzzi; Mauro Ferrari
Journal:  Pharmacol Res       Date:  2010-01-05       Impact factor: 7.658

Review 6.  Active targeted delivery of immune therapeutics to lymph nodes.

Authors:  Baharak Bahmani; Ishaan Vohra; Nazila Kamaly; Reza Abdi
Journal:  Curr Opin Organ Transplant       Date:  2018-02       Impact factor: 2.640

Review 7.  PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution.

Authors:  Zahid Hussain; Shahzeb Khan; Muhammad Imran; Muhammad Sohail; Syed Wadood Ali Shah; Marcel de Matas
Journal:  Drug Deliv Transl Res       Date:  2019-06       Impact factor: 4.617

8.  Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug.

Authors:  Olga B Garbuzenko; Maha Saad; Seema Betigeri; Min Zhang; Alexandre A Vetcher; Viatcheslav A Soldatenkov; David C Reimer; Vitaly P Pozharov; Tamara Minko
Journal:  Pharm Res       Date:  2008-10-29       Impact factor: 4.200

Review 9.  Drug distribution in tumors: mechanisms, role in drug resistance, and methods for modification.

Authors:  Antonello Di Paolo; Guido Bocci
Journal:  Curr Oncol Rep       Date:  2007-03       Impact factor: 5.075

Review 10.  Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine.

Authors:  Melanie Kripp; Ralf-Dieter Hofheinz
Journal:  Int J Nanomedicine       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.